Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of a 6 weeks memantine
add-on to risperidon treatment for the prevention of cognitive dysfunction and negative
symptomatology in patients with acute schizophrenia.
Psychopathological changes were assessed with the Positive and Negative Syndrome Scale
(PANSS) at baseline and after 2, 4, 6, 12, and 24 weeks. Cognitive function were measured at
baseline and week 6, and 24 by the California Verbal Learning Test, Benton Learning Test,
Digit Span Forward and Backward Test, Continuous Performance Test, Stroop Test, Trail-Making
Test, Verbal Fluency Test, and Wisconsin Card Sorting Test.